Doug Leedy

Cardiologist at UW Medicine | cardio-oncology

[Ronald Witteles @Ron_Witteles]

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a special thanks to all of the patients who participated in the clinical trials. This is how #sciencemovesforward! 🍾https://t.co/9r69ULYrWn

[Eric H Yang, MD @datsunian]

#cardioonc has had 🚀rise in interest & science, leading to a plethora of guidelines & consensus statements.

But where do stand on LOE & $/resource effective care?

@djleedy @Richardkcheng2 et al do a deep dive on strengths & gaps & how to fill them.
https://t.co/6SIrbleHDt
2/🧵

[Richardkcheng @Richardkcheng2]

Blood Pressure and Cardiovascular Risk in Women With Breast Cancer. https://t.co/0CnWcHJsYV we sought to better characterize the association between BP and CVD in a large cohort of BC patients utilizing the Kaiser Pathways Study. Led by @djleedy @JamalRanaMD @fredhutch

[Doug Leedy @djleedy]

@VidYogeswaran @Richardkcheng2 @Kirkpatj1 Congrats all. Great study!

[Heart_BMJ @Heart_BMJ]

Transcatheter aortic valve intervention in patients with cancer
https://t.co/gM7wlXKE9H

[Richardkcheng @Richardkcheng2]

Hot off the press 🔥🔥 - review on use of tavr in cancer patients from our spectacular fellows @djleedy and @DavidElison1, led by @jamiemccabeMD in BMJ Heart - what do we know and where are the gaps? #cardioonc @AnaBaracCardio @datsunian @mmamas1973 @Heart_BMJ @UWMedHeart

[Doug Leedy @djleedy]

@VidYogeswaran @Richardkcheng2 @Kirkpatj1 Great work, Vid!

[Richardkcheng @Richardkcheng2]

Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis | Journal of the American Heart Association - It is often stated that attr amyloid patients don’t tolerate nh blockade but there is limited data https://t.co/yZJ0bxNQLX

[Richardkcheng @Richardkcheng2]

Thank you to my coauthors and Mat for his mentorship @WCL92689433 @ParagGoyalMD @JanMGriffin @djleedy @mathew_maurer

[Richardkcheng @Richardkcheng2]

Nice review led by our former HF fellow - Minnu- on implications of cancer before and after heart transplant @AnaBaracCardio @datsunian @avirupguha @KiranKhush1 @Heart_BMJ @WCL92689433 @Ron_Witteles @drbrowncares

[Richardkcheng @Richardkcheng2]

Coronary revascularisation outcomes in patients with cancer | Heart - Great work by our fellow Doug Leedy! ⁦@djleedy⁩ ⁦@mmamas1973⁩ ⁦@JTiwanaMD⁩ ⁦@Ravi_Hira_MD⁩ ⁦@Heart_BMJ⁩ ⁦ https://t.co/TlHYwXe9bT

[Mamas A. Mamas @mmamas1973]

Congratulations to @djleedy⁩ and @Richardkcheng2
on leading our review around revascularisation in #Cardionc #cancer patients https://t.co/TYTrtPSyIB thank you for invitingh me to contribute @ShrillaB @SukhNijjer @ncurzen @ShaziaTHussain1 @lamelaspablo @adityadoc1 @Hragy

[Richardkcheng @Richardkcheng2]

The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative - European Journal of Heart Failure - Wiley Online Library - ⁦@AnaBaracCardio⁩ ⁦@fredhutch⁩ ⁦@datsunian⁩ ⁦@djleedy⁩ https://t.co/XQzT46THRE

[American College of Cardiology @ACCinTouch]

JUST RELEASED: New ACC/@American_Heart #cvVHD Guideline provides updated recommendations & expanded treatment options based on the latest evidence. Access the full guideline in #JACC, and related clinician & patient tools in our VHD Guideline Hub: https://t.co/ZqckoMVb5o

[JACC Journals @JACCJournals]

Baseline strain parameters predict post-hematopoietic stem cell transplantation (HSCT) survival in AL amyloidosis patients free of clinical #heartfailure pre-HSCT. Drs. @Richardkcheng2, @djleedy et al. discuss in #JACCCardioOnc. https://t.co/GJLnawQhNI

[Eric Topol @EricTopol]

A window to a bright side of #COVID19: the humanistic #healthcare pros on the front lines
“Everyone is worried about not having sufficient ventilators. I am worried about not having sufficient compassion and not having sufficient people.”
--@nickmmark
@NEJM by @LisaRosenbaum17